CA3004509A1 - Plasminogen dosage regimen for wound healing - Google Patents

Plasminogen dosage regimen for wound healing Download PDF

Info

Publication number
CA3004509A1
CA3004509A1 CA3004509A CA3004509A CA3004509A1 CA 3004509 A1 CA3004509 A1 CA 3004509A1 CA 3004509 A CA3004509 A CA 3004509A CA 3004509 A CA3004509 A CA 3004509A CA 3004509 A1 CA3004509 A1 CA 3004509A1
Authority
CA
Canada
Prior art keywords
wound
plasminogen
medicament
biologically active
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3004509A
Other languages
English (en)
French (fr)
Inventor
Ulf BERTHEIM
Tor Ny
Pierre Laurin
Martin Robitaille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Ltd
Original Assignee
Prometic Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Ltd filed Critical Prometic Biotherapeutics Ltd
Publication of CA3004509A1 publication Critical patent/CA3004509A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3004509A 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing Abandoned CA3004509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253352P 2015-11-10 2015-11-10
US62/253,352 2015-11-10
PCT/IB2016/001606 WO2017081529A1 (en) 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing

Publications (1)

Publication Number Publication Date
CA3004509A1 true CA3004509A1 (en) 2017-05-18

Family

ID=57485826

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3004509A Abandoned CA3004509A1 (en) 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing

Country Status (14)

Country Link
US (1) US20180326023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3373957A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534306A (cg-RX-API-DMAC7.html)
KR (1) KR20180070708A (cg-RX-API-DMAC7.html)
CN (1) CN108289934A (cg-RX-API-DMAC7.html)
AU (1) AU2016352183A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009476A8 (cg-RX-API-DMAC7.html)
CA (1) CA3004509A1 (cg-RX-API-DMAC7.html)
IL (1) IL259172A (cg-RX-API-DMAC7.html)
MX (1) MX2018005876A (cg-RX-API-DMAC7.html)
RU (1) RU2018121234A (cg-RX-API-DMAC7.html)
TW (1) TW201722464A (cg-RX-API-DMAC7.html)
WO (1) WO2017081529A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803010B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN111432762B (zh) * 2017-12-15 2023-01-13 墨尼克医疗用品有限公司 预防性敷料
BR112020003022A2 (pt) 2017-12-26 2020-08-25 Hirotaro Fukuoka composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo
JP7682567B2 (ja) * 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ngfレベルを増加させる方法及び薬剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法

Also Published As

Publication number Publication date
WO2017081529A1 (en) 2017-05-18
MX2018005876A (es) 2018-11-09
EP3373957A1 (en) 2018-09-19
RU2018121234A3 (cg-RX-API-DMAC7.html) 2020-03-12
AU2016352183A1 (en) 2018-06-28
TW201722464A (zh) 2017-07-01
CN108289934A (zh) 2018-07-17
KR20180070708A (ko) 2018-06-26
US20180326023A1 (en) 2018-11-15
ZA201803010B (en) 2019-07-31
IL259172A (en) 2018-06-28
JP2018534306A (ja) 2018-11-22
BR112018009476A8 (pt) 2019-02-26
RU2018121234A (ru) 2019-12-13
BR112018009476A2 (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
Kalani et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers: long-term follow-up
US9962402B2 (en) Healing composition for topical application
US20100035798A1 (en) Methods and compositions for the topical oxygenation of hypoxic tissue
US20180326023A1 (en) Plasminogen dosage regimen for wound healing
BRPI0215214B1 (pt) uso do fator de crescimento epidérmico, e, composição farmacêutica
Liu et al. Experimental study on the effect of chrysin on skin injury induced by amiodarone extravasation in rats
TAŞBAKAN et al. Intralesional epidermal growth factor therapy fordiabetic foot ulcers: an evaluation of 15 cases
US20230338296A1 (en) Devices and methods for delivery of oxygen to a wound
Lai et al. The establishment and evaluation of a swine model of deinagkistrodon acutus snakebite envenomation
RU2734159C1 (ru) Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием
CN113975378A (zh) 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用
Elkeles et al. ABC of vascular diseases. The diabetic foot
Edmonds A natural history and framework for managing diabetic foot ulcers
US12521392B2 (en) Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias
Ji et al. Nursing care for diabetic toe ulcers: A case series report and literature review
Pergolizzi et al. Surgical Indications in All Diagnostic and Care Pathways (DTCP) Settings
Taylor et al. Basics of chronic wound care
Pavlovich et al. Injecting material for skin regeneration Lacerta application in treatment of trophic ulcers in patients with diabetic foot syndrome
REKHA A COMPARATIVE STUDY OF COLLAGEN
Edmonds 21 Diabetic Foot Ulcers
Mueller Foot infection in the elderly
BOLGARSKA et al. New Methods of Treatment for Trophic Lesions of the Lower Extremities in Patients with Diabetes Mellitus
Brill et al. New therapeutic options for lower-extremity ulcers.
Jiao et al. Dan University, West Yan’an Road 221, Jing’an District, Shanghai, China, 200040 Jiao-jiao Bai: the corresponding author, chief superintendent nurse, professor, deputy director, Nursing Department of Hua Dong Hospital Affiliated to Fu Dan University, West Yan’an Road 221, Jing’an District, Shanghai, China, 200040. Email: bjj163163@ 163. com or blsyx02@ 126. com, Tel: 13331806987
BR112020012384A2 (pt) método de tratamento de úlceras do pé diabético

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220510